OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
March 17, 2023
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
January 03, 2023
Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.
September 03, 2022
It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.
May 03, 2022
Inhalation formulations are complex, and empirical data are essential for realizing optimal solutions.
November 03, 2021
Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.
October 15, 2021
Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.
September 13, 2021
When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.
September 03, 2021
The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.
August 27, 2021
FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.
August 01, 2021
The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.